NCT02035111 is a Phase 4 clinical trial of Tianshu capsule in Migraine, sponsored by Jiangsu Kanion Pharmaceutical Co., Ltd.

Who is sponsoring NCT02035111?

NCT02035111 is sponsored by Jiangsu Kanion Pharmaceutical Co., Ltd.

What drugs are being tested in NCT02035111?

Interventions in NCT02035111: Tianshu capsule, Sugar pill.

Is NCT02035111 still recruiting?

NCT02035111 is currently completed. Last updated 13 April 2016.

Last reviewed 2016-04-13 · How we verify

NCT02035111

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Evaluate the Safety and the Efficacy of Tianshu Capsule Treating Migraine in a Randomized, Placebo-Controlled, Double-blind, Multicenter Study.

Completed Phase 4 Last updated 13 April 2016

What this trial tests

Phase 4 trial testing Tianshu capsule in Migraine in 947 participants. Completed in 1 November 2015.

Timeline

1 March 2014

Primary endpoint
1 April 2015

1 November 2015

Quick facts

Lead sponsor	Jiangsu Kanion Pharmaceutical Co., Ltd
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	947
Start date	1 March 2014
Primary completion	1 April 2015
Estimated completion	1 November 2015
Sites	20 locations across China

Drugs / interventions tested

Tianshu capsule — full drug profile →
Sugar pill

Conditions studied

Migraine — all drugs for Migraine →

Sponsor

Jiangsu Kanion Pharmaceutical Co., Ltd — full company profile →

Who can join

Adults 18 to 65, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in the frequency of attack of Migraine Per 4 weeks at Week 16 from baseline
Time frame: -4w,0,4w,8w,12w,16w

Sponsor's own description

The purpose of this study is to evaluate the safety and the efficacy of Tianshu capsule treating Migraine Headache.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial.
Yu S, Ran Y, Xiao W, Tang W, et al · · 2019 · cited 14× · PMID 31842860 · DOI 10.1186/s12906-019-2775-2

Verify or expand the search:

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Other Jiangsu Kanion Pharmaceutical Co., Ltd trials

Trials by the same sponsor.

NCT07126171 — A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever · NA · not yet recruiting
NCT06679998 — A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection · Phase 1 · not yet recruiting
NCT05192304 — Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia · Phase 1 · unknown
NCT07200362 — Study of Compound Nanxing Zhitong Ointment in the Treatment of Chronic Pain in Musculoskeletal System · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02035111 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Kanion Pharmaceutical Co., Ltd
Last refreshed: 13 April 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02035111.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing